We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $10.2B
1-Year Est. Return 149.19%
This Fund
S&P 500
This Quarter Est. Return
+30.6%
1 Year Est. Return
+149.19%
3 Year Est. Return
+425.03%
5 Year Est. Return
+775.33%
10 Year Est. Return
+45,729.2%
AUM
$450M
AUM Growth
+$163M
Cap. Flow
+$151M
Cap. Flow %
33.61%
Top 10 Hldgs %
64.43%
Holding
49
New
11
Increased
19
Reduced
9
Closed
7

Top Buys

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$25.1M
2
BMY icon
Bristol-Myers Squibb
BMY
+$19.1M
3
TSRO
TESARO, Inc.
TSRO
+$16.2M
4
GBT
Global Blood Therapeutics, Inc.
GBT
+$15.2M
5
DERM
Dermira, Inc.
DERM
+$15.1M

Top Sells

Rank Stock Value
1
ANAC
ANACOR PHARMACEUTICALS INC COM
ANAC
+$8.91M
2
GILD icon
Gilead Sciences
GILD
+$5.94M
3
CPXX
CELATOR PHARMACEUTICALS INC. COMMON STOCK
CPXX
+$5.92M
4
PTX
Pernix Therapeutics Holdings, Inc.
PTX
+$4.08M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$3.02M

Sector Composition

Rank Sector Weight
1 Healthcare 73.15%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
FBIO icon
26
Fortress Biotech
FBIO
$111M
$3.57M 0.79%
88,442
-749
-0.8% -$34.9K
SRPT icon
27
CALL
Sarepta Therapeutics
SRPT
$1.64B
$2.6M 0.58%
624,600
+317,100
+103% +$5.87M
INNL
28
DELISTED
Innocoll Holdings plc Ordinary Shares
INNL
$2.58M 0.57%
+468,148
New +$3.83M
TRIL
29
DELISTED
Trillium Therapeutics Inc.
TRIL
$2.05M 0.46%
228,697
– –
SRPT icon
30
PUT
Sarepta Therapeutics
SRPT
$1.64B
$2.01M 0.45%
+1,332,000
New +$24.7M
OTLK icon
31
Outlook Therapeutics
OTLK
$187M
$1.59M 0.35%
+2,917
New +$1.74M
ASMB icon
32
Assembly Biosciences
ASMB
$498M
$1.45M 0.32%
+21,749
New +$1.43M
CLLS
33
Cellectis
CLLS
$288M
$1.14M 0.25%
42,671
+17,671
+71% +$518K
LJPC
34
DELISTED
La Jolla Pharmaceutical Company
LJPC
$1.12M 0.25%
70,000
-141,672
-67% -$2.54M
CRVS icon
35
Corvus Pharmaceuticals
CRVS
$1.1B
$1.07M 0.24%
74,800
– –
VCEL icon
36
Vericel Corp
VCEL
$2.38B
$574K 0.13%
255,000
-20,000
-7% -$57.6K
IBRX icon
37
ImmunityBio
IBRX
$7.15B
$450K 0.1%
72,412
-122,500
-63% -$951K
ONSIW
38
DELISTED
Oncobiologics, Inc. Series A Warrant Expiring 2/18/2019
ONSIW
$107K 0.02%
+233,333
New +$89.3K
ONSIZ
39
DELISTED
Oncobiologics, Inc. Series B Warrant
ONSIZ
$105K 0.02%
+233,333
New +$123K
IMMU
40
CALL
DELISTED
Immunomedics Inc
IMMU
$64K 0.01%
+453,900
New +$1.52M
OEF icon
41
PUT
iShares S&P 100 ETF
OEF
$19.5B
$19K ﹤0.01%
50,000
-200,000
-80% -$18.4M
GYRE icon
42
Gyre Therapeutics
GYRE
$629M
– –
-636
Closed -$120K
PGEN icon
43
CALL
Precigen
PGEN
$1.94B
– –
-201,800
Closed -$60K
XNTK icon
44
PUT
State Street SPDR NYSE Technology ETF
XNTK
$1.94B
– –
-750,000
Closed -$670K
EGLT
45
DELISTED
Egalet Corporation
EGLT
– –
-233,334
Closed -$1.6M
AEGR
46
DELISTED
Aegerion Pharmaceuticals
AEGR
– –
-306,800
Closed -$1.14M
PTX
47
DELISTED
Pernix Therapeutics Holdings, Inc.
PTX
– –
-388,990
Closed -$4.08M
ANAC
48
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
– –
-166,700
Closed -$8.91M
1
2

Similar funds

IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
WAM
Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

Avoro Capital Advisors's Q2 2016 Portfolio in Review

As of Q2 2016, Avoro Capital Advisors held 49 positions worth $450M, up 57% from $287M the previous quarter. Its ten largest holdings account for 64% of the portfolio.

Avoro Capital Advisors deployed $151M of net new capital in Q2 2016, opening 11 new positions and adding to 19 existing holdings. Its largest new stake was Acadia Pharmaceuticals: 329,500 shares worth $10.7M.

By sector, the portfolio is most concentrated in Healthcare at 73% of assets, down from 81% a quarter earlier.

On the sell side, the largest reduction was Gilead Sciences, an estimated $5.94M trimmed.

  • Avoro Capital Advisors's largest Q2 2016 buy was Acadia Pharmaceuticals: 329,500 shares worth $10.7M.
  • Avoro Capital Advisors added most to Immunomedics Inc in Q2 2016, an estimated $25.1M increase.
  • Avoro Capital Advisors's biggest Q2 2016 reduction was Gilead Sciences, cutting an estimated $5.94M.
  • Avoro Capital Advisors fully exited ANACOR PHARMACEUTICALS INC COM in Q2 2016, selling an estimated $8.91M.
  • Avoro Capital Advisors's ten largest holdings make up 64% of its $450M portfolio in Q2 2016.
  • Avoro Capital Advisors opened 11 new positions and closed 7 in Q2 2016.
  • Avoro Capital Advisors's portfolio value rose 57% quarter-over-quarter to $450M.

Based on Avoro Capital Advisors's 13F filing for Q2 2016, filed 15 Aug 2016.